Raaj Medisafe India Ltd. (RAAJMEDI) — Tipsheet https://tipsheet.markets/company/raajmedi/ Every Tipsheet Editorial note covering Raaj Medisafe India Ltd. (RAAJMEDI), newest first. Grounded in BSE/NSE primary-source filings. en-in Fri, 10 Jul 2026 15:47:44 GMT Raaj Medisafe CFO quits after Fabrizo deal, raises oversight questions https://tipsheet.markets/raajmedi-raaj-medisafe-cfo-quits-after-fabrizo-deal-raises-oversight-questions-120981/ https://tipsheet.markets/raajmedi-raaj-medisafe-cfo-quits-after-fabrizo-deal-raises-oversight-questions-120981/ Fri, 10 Jul 2026 17:35:51 GMT The resignation of CFO Kanije Fatema Dadani Patel comes just after a transformational acquisition, leaving a nano-cap with thin management depth in a critical moment. The resignation of CFO Kanije Fatema Dadani Patel comes just after a transformational acquisition, leaving a nano-cap with thin management depth in a critical moment.

What’s new

  • CFO Kanije Fatema Dadani Patel resigned citing professional and personal reasons.
  • Resignation effective July 14, 2026; board accepted and sought smooth transition.
  • Departure follows Raaj Medisafe's transformational acquisition of Fabrizo Industries plant and machinery.

Why it matters

For a nano-cap with a market cap of just ₹119 cr and trailing PAT down 192.7%, the CFO's exit shortly after a major acquisition creates a vacuum in financial oversight. With limited management depth, investor trust in post-deal financial discipline is at stake.

What we’re watching

  • Timeline for appointing a new CFO and transition details.
  • Q1 FY27 results for any signs of control lapses or strategic drift.
  • Any additional disclosures on the Fabrizo integration progress.

The full read

Raaj Medisafe India, a nano-cap with a market cap of approximately ₹119 crores, just lost its CFO. Kanije Fatema Dadani Patel resigned effective July 14, citing new opportunities and personal reasons. Bad timing. The departure lands right after the company announced a transformational acquisition—plant and machinery from Fabrizo Industries. For a firm with ₹25 crores in quarterly sales and a trailing profit decline of 192.7%, management depth is thin. Losing the top financial officer at such a moment raises questions about oversight of the deal and financial controls. The board asked Patel to ensure a smooth transition, but it hasn't named a successor. The next quarterly report will be the first test of whether operations remain on track without a CFO.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial Raaj Medisafe posts FY26 results, addresses routine board items https://tipsheet.markets/raajmedi-raaj-medisafe-posts-fy26-results-addresses-routine-board-items-103425/ https://tipsheet.markets/raajmedi-raaj-medisafe-posts-fy26-results-addresses-routine-board-items-103425/ Fri, 29 May 2026 19:16:18 GMT The nano-cap company filed its annual audited results alongside standard approvals on related-party transactions and preferential allotment fund usage. The nano-cap company filed its annual audited results alongside standard approvals on related-party transactions and preferential allotment fund usage.

What’s new

  • Raaj Medisafe's board approved its audited financial results for Q4 and FY26.
  • The board also approved related-party transactions and reviewed fund utilization from a recent preferential allotment.
  • The filing is a routine annual compliance disclosure.

Why it matters

For a nano-cap like Raaj Medisafe, these annual results are the primary window into the business. The filing confirms the company is current with its compliance obligations, but it contains no strategic surprises or new financial data beyond the standard filings.

What we’re watching

  • Any commentary on revenue growth or margins from the audited numbers once they are parsed.
  • Details on the preferential allotment fund deployment timeline.
  • Any changes in related-party transaction volumes or terms.

The full read

Raaj Medisafe India, a ₹146 crore market-cap company, has filed its FY26 annual audited results. The board approved the numbers at a May 29 meeting that also ticked off standard governance boxes: related-party transactions and a check on the money from a recent preferential allotment. For investors tracking the nano-cap, this is a compliance event, not a catalyst. The headline is that the company is up to date with its filings. The next step is parsing the actual numbers in the full results statement to see if there's a story in the financials themselves.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial